Compare Oscar Health Inc (OSCR) vs Uber Technologies Inc (UBER) Price & Performance

Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.

The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.

Uber's stock trades at $72.17, down 0.4% on the day, with a bearish technical signal from moving averages. The company reported strong revenue growth to $52.02B in 2025 and a net income of $10.05B, though earnings have been mixed with a recent miss in Q4 2025. Positive cash flow from operations reached $10.10B, and analyst sentiment remains overwhelmingly bullish with an 81.67% buy rating and a consensus price target of $107.64. Recent news highlights strategic moves in autonomous vehicles, including robotaxi pilots in Madrid and Munich.

The outlook for Uber is positive due to robust revenue growth, expanding profitability, and strong analyst support, but risks include competitive pressures in key markets like India, execution challenges in autonomous driving initiatives, and potential cost overruns from AI investments. The stock offers upside potential if it meets earnings expectations and successfully scales new technologies, though investors should monitor competitive dynamics and regulatory developments.